Alira Health enhances market access services via Centivis partnership

“We are honored to join forces with Centivis, an up-and-coming niche provider in the space with deep insight into the nuances of diagnostics access models,” said Richard Charter, Alira Health’s Vice President of MedTech Market Access for Europe & Asia Pacific.

“The diagnostics industry is transforming rapidly. More complex solutions and increasing regulatory and evidence requirements demand better, value-based access solutions serving patient needs,” said Norbert Farkas, Founder and Managing Partner of Centivis AG. “We are pleased to collaborate with Alira Health. Alira Health’s broad range of tech-enabled consulting and advisory services, complemented by its mission to humanize healthcare, is where our industry is headed.”

About Centivis:

Centivis, founded in 2018, is a boutique (digital) diagnostics market access consulting firm that combines well-proven pharmaceutical market access methodology with specific diagnostics knowledge tested in real-life, industry settings. Centivis has successfully supported leading diagnostics manufacturers, innovative pharmaceuticals, and digital diagnostics scale-ups in launching novel diagnostics solutions, predictive algorithms, and decision support tools in various therapy areas and across technology platforms. Learn more at: www.centivis.com

About Alira Health:

Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence. Alira Health’s integrated and multidisciplinary team of over 600 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.